Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Price Target Raised to $40.00

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) had its price target raised by Wedbush from $35.00 to $40.00 in a report issued on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Other analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Royal Bank Of Canada began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective for the company. TD Cowen began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They set a “buy” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Damora Therapeutics, Inc. Common Stock Trading Down 0.8%

Damora Therapeutics, Inc. Common Stock stock opened at $28.99 on Thursday. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.45 and a 12 month high of $38.33. The stock’s 50 day simple moving average is $26.00 and its two-hundred day simple moving average is $26.06. The firm has a market cap of $1.78 billion, a PE ratio of -5.20 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, equities research analysts forecast that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter valued at approximately $76,000. Virtu Financial LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $49,000. Connective Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter worth approximately $100,000. Sigma Planning Corp acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth approximately $334,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth approximately $266,000. 14.20% of the stock is currently owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.